Literature DB >> 2988982

Profile of activity of kappa receptor agonists in the rabbit vas deferens.

A Hayes, A Kelly.   

Abstract

The purpose of this study was to investigate further the kappa opioid receptor selectivity of the field-stimulated isolated rabbit vas deferens preparation and to study the profile of a series of kappa agonists in this tissue. Agonists acting at mu, delta and sigma receptors were without detectable effect in the rabbit vas deferens. But a number of kappa agonists, including bremazocine, tifluadom, ethylketocyclazocine, ketocyclazocine, U-50,488 and Win 42,610 all depressed contractions, producing parallel dose-response curves. Mr 2034 generally produced a shallower dose-response curve and achieved a lower maximum effect, thus acting like a partial agonist. The effect of ethylketocyclazocine was not reduced by the irreversible mu antagonist, beta-funaltrexamine, confirming that it is not acting via mu receptors. Another group of drugs, including nalorphine, butorphanol and proxorphan, which produce an agonist action via kappa receptors in the guinea-pig ileum and mouse vas deferens, were antagonists in the rabbit vas deferens, suggesting that this tissue will only respond to high efficacy kappa agonists.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2988982     DOI: 10.1016/0014-2999(85)90558-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Discriminative stimulus effects of serotonin agonists, neutral antagonists, and inverse agonists in pigeons: perspectives on intrinsic efficacy measurements in vivo.

Authors:  Martilias Farrell; Sharon Rosenzweig-Lipson; Ellen Walker
Journal:  Psychopharmacology (Berl)       Date:  2010-06-05       Impact factor: 4.530

2.  Inability of an opioid antagonist lacking negative intrinsic activity to induce opioid receptor up-regulation in vivo.

Authors:  B J Morris; M J Millan
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

3.  Spinal antinociceptive actions and naloxone reversibility of intravenous mu- and kappa-opioids in spinalized rats: potency mismatch with values reported for spinal administration.

Authors:  C G Parsons; D C West; P M Headley
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

4.  Differential sensitivity of models of antinociception in the rat, mouse and guinea-pig to mu- and kappa-opioid receptor agonists.

Authors:  A G Hayes; M J Sheehan; M B Tyers
Journal:  Br J Pharmacol       Date:  1987-08       Impact factor: 8.739

5.  Pharmacological profile of various kappa-agonists at kappa-, mu- and delta-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the rat brain.

Authors:  A H Mulder; D M Burger; G Wardeh; F Hogenboom; A L Frankhuyzen
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

6.  Determination of the receptor selectivity of opioid agonists in the guinea-pig ileum and mouse vas deferens by use of beta-funaltrexamine.

Authors:  A G Hayes; M J Sheehan; M B Tyers
Journal:  Br J Pharmacol       Date:  1985-12       Impact factor: 8.739

7.  Reversal by beta-funaltrexamine of the antinociceptive effect of opioid agonists in the rat.

Authors:  A G Hayes; M Skingle; M B Tyers
Journal:  Br J Pharmacol       Date:  1986-08       Impact factor: 8.739

8.  ICI 204448: a kappa-opioid agonist with limited access to the CNS.

Authors:  J S Shaw; J A Carroll; P Alcock; B G Main
Journal:  Br J Pharmacol       Date:  1989-04       Impact factor: 8.739

9.  Guanine nucleotide-binding protein-coupled and -uncoupled states of opioid receptors and their relevance to the determination of subtypes.

Authors:  A Richardson; C Demoliou-Mason; E A Barnard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  In vitro study of the interaction of salmon calcitonin with mu, delta and kappa opioid agonists.

Authors:  M I Martín; M J Alfaro; C Goicoechea; M I Colado
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-03       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.